Sglt2 Inhibitor

The FDA will review an oral testosterone undecanoate softgel manufactured by Marius Pharmaceuticals as a potential treatment for hypogonadism in men. The announcement was the top story in endocrinology last week.

Type 2 diabetes agents with proven cardiovascular benefit may be useful for patients with type 1 diabetes to prevent atherosclerotic CVD, but more robust data are needed for the type 1 population.

SGLT2 inhibitors provide limited glycemic management benefits and may not be cost-effective for most people with type 2 diabetes, according to a study published in the Journal of Diabetes and Its Complications.

Adults with type 2 diabetes assigned an SGLT2 inhibitor or a GLP-1 receptor agonist during cardiovascular outcomes trials derived benefit from the therapies regardless of whether they were prescribed insulin, according to a meta-analysis.

Healio and Cardiology Today present highlights from the virtual American Heart Association Scientific Sessions, held Nov. 13 to 17.

Healio and Cardiology Today have curated a list of the top news of 2020 in diabetes and the heart.

For patients with type 2 diabetes, SGLT2 inhibitors conferred a lower risk of developing AKI than use of GLP-1 receptor agonists or dipeptidyl peptidase-4 inhibitors, according to a network meta-analysis of clinical trials.

The FDA has granted priority review to Farxiga, from AstraZeneca, for the treatment of chronic kidney disease.

The FDA recently expanded the approval of liraglutide for chronic weight management in adolescents with obesity. It was the top story in endocrinology last week.

Type 2 diabetes agents with proven cardiovascular benefit may be useful for patients with type 1 diabetes to prevent atherosclerotic CVD, but more robust data are needed for the type 1 population, according to two speakers who debated the issue.